Sarepta Therapeutics (NASDAQ:SRPT) Cut to “Hold” at Wall Street Zen

Wall Street Zen downgraded shares of Sarepta Therapeutics (NASDAQ:SRPT) from a buy rating to a hold rating in a research note issued to investors on Saturday.

Other equities research analysts have also issued research reports about the stock. Wolfe Research raised shares of Sarepta Therapeutics from a “peer perform” rating to an “outperform” rating and set a $27.00 target price on the stock in a report on Thursday, July 9th. Weiss Ratings downgraded shares of Sarepta Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a report on Wednesday, August 5th. Zacks Research downgraded shares of Sarepta Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 7th. HC Wainwright restated a “buy” rating on shares of Sarepta Therapeutics in a research report on Tuesday, July 28th. Finally, Piper Sandler decreased their price objective on shares of Sarepta Therapeutics from $23.00 to $20.00 and set a “neutral” rating on the stock in a research note on Thursday, July 9th. Nine investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and six have issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $25.06.

Sarepta Therapeutics Stock Performance

Shares of NASDAQ:SRPT opened at $17.18 on Friday. The business’s fifty day moving average price is $16.91 and its two-hundred day moving average price is $18.46. Sarepta Therapeutics has a fifty-two week low of $14.68 and a fifty-two week high of $25.32. The stock has a market capitalization of $1.81 billion, a price-to-earnings ratio of -5.92, a price-to-earnings-growth ratio of 0.22 and a beta of 0.24. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.42 and a quick ratio of 2.62.

Hedge Funds Weigh In On Sarepta Therapeutics

Institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. raised its position in shares of Sarepta Therapeutics by 9.2% during the fourth quarter. Vanguard Group Inc. now owns 11,810,729 shares of the biotechnology company’s stock worth $254,167,000 after acquiring an additional 993,283 shares during the last quarter. M&T Bank Corp bought a new position in Sarepta Therapeutics in the fourth quarter valued at about $1,794,000. CWM LLC boosted its holdings in Sarepta Therapeutics by 230.8% in the fourth quarter. CWM LLC now owns 240,536 shares of the biotechnology company’s stock valued at $5,176,000 after acquiring an additional 167,831 shares during the last quarter. Y Intercept Hong Kong Ltd bought a new position in Sarepta Therapeutics in the first quarter valued at about $1,935,000. Finally, Merit Financial Group LLC acquired a new stake in Sarepta Therapeutics in the fourth quarter worth about $820,000. 86.68% of the stock is owned by institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.